Belsomra

Belsomra, also known as suvorexant, is a non-benzodiazepine hypnotic agent used for the treatment of insomnia. It is a medication that helps individuals with difficulty initiating or maintaining sleep.

Belsomra works by blocking the activity of certain neurotransmitters in the brain that can interfere with sleep, such as orexin and melanin-concentrating hormone (MCH). By blocking these neurotransmitters, the medication helps to slow down the brain activity that is associated with wakefulness and promotes a state of drowsiness.

Belsomra is available in a once-daily form, typically taken within 30 minutes of going to bed. The medication is not a sleep aid, and it does not cure insomnia, but rather provides a single dose that can help individuals fall asleep and stay asleep for a significant portion of the night.

Belsomra may interact with other medications, and individuals should inform their healthcare provider about any medications they are currently taking, including prescription and over-the-counter medications, vitamins, and herbal supplements.

The most common side effects associated with Belsomra include dizziness, headaches, and sleep paralysis. More severe side effects, such as hallucinations, anxiety, and muscle weakness, have been reported in some cases, although these are rare.

Belsomra is an FDA-approved medication that has been extensively studied in clinical trials. The medication's safety and effectiveness were evaluated in several studies involving over 3,000 participants with insomnia, and the results have shown that Belsomra can be an effective treatment option for this condition.